Pulmatrix, Inc. (PULM)
| Market Cap | 4.78M -73.0% |
| Revenue (ttm) | n/a |
| Net Income | -4.03M |
| EPS | -1.10 |
| Shares Out | 3.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,122 |
| Open | 1.330 |
| Previous Close | 1.350 |
| Day's Range | 1.291 - 1.390 |
| 52-Week Range | 1.060 - 4.980 |
| Beta | 1.92 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 24, 2026 |
About PULM
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in ch... [Read more]
Financial Performance
Financial StatementsNews
Eos SENOLYTIX's PTC-2105 Reduced Semaglutide-Associated Lean-Mass Loss in Aged Mice: Data to Be Presented at 19th Sarcopenia, Cachexia & Wasting Disorders International Conference
Data to highlight PTC-2105's attenuation of terminal lean-mass decline and semaglutide-associated lean-mass loss in aged mice PTC-2105 is Eos's lead clinical candidate in development for elderly patie...
Eos SENOLYTIX Reports Interim Data Showing Preserved Physical Function with MitoXcel Geropeptide PTC-2105 in a Second Species, Aged-Rat Study
Interim Results in Super-Aged Rats Tested Externally Show Preserved Motor Performance and Reduced Fat Mass, Consistent with Prior Findings in Aged Mice Tested at Eos's R&D Facility; Data Support IND-E...
Pulmatrix Transcript: EGM 2026
Eight proposals covered the Eos merger, reverse split, authorized shares, auditor, directors, executive pay and incentive plan. Preliminary results showed sufficient votes for the nominees and all other proposals; final totals were to be filed with the SEC.
Eos SENOLYTIX Presents Late-Life Survival and Healthspan Data for Mitochondria-Targeted Geropeptide PTC-2105 at the 17th World Congress on Targeting Mitochondria, and Launches “Team Speedy” to Let the Public Follow Its Longest-Lived Mouse
In naturally aged mice treated from 80 weeks of age and followed until natural death, once-weekly PTC-2105 (25 mg/kg) significantly increased overall survival versus saline (log-rank p = 0.0142) “Spee...
Pulmatrix Proxy statement: Proxy filing
Pulmatrix filed a proxy statement on October 7, 2026, providing details for shareholder voting and corporate governance matters.
Pulmatrix Registration statement: Registration filing
Pulmatrix filed a registration statement on October 5, 2026, providing details about a securities offering with the SEC.
Pulmatrix Proxy statement: Proxy filing
Pulmatrix filed a proxy statement on September 25, 2026, providing details for shareholder voting and corporate governance matters.
Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting Mitochondria
Founder and CEO Kevin Slawin, M.D., to deliver industry keynote on advancing mitochondrial-targeted geropeptide medicine Eos advancing lead candidate MitoXcel™ geropeptide PTC-2105 toward first-in-hum...
Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger
Form S-4 filed related to the announced merger agreement with Eos SENOLYTIX FRAMINGHAM, Mass., Aug. 13, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmac...
Pulmatrix Earnings release: Q2 2026
Pulmatrix released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Pulmatrix Quarterly report: Q2 2026
Pulmatrix has published its Q2 2026 quarterly earnings report on August 13, 2026.
Pulmatrix Registration statement: Registration filing
Pulmatrix filed a registration statement on August 7, 2026, providing details about a securities offering with the SEC.
Pulmatrix Registration statement: Registration filing
Pulmatrix filed a registration statement on June 4, 2026, providing details about a securities offering with the SEC.
Pulmatrix files to sell 490,910 shares of common stock for holders
06:13 EDT Pulmatrix (PULM) files to sell 490,910 shares of common stock for holders
Pulmatrix Announces First Quarter 2026 Financial Results
Announced merger agreement with Eos SENOLYTIX in March Closed private placement of preferred stock FRAMINGHAM, Mass., May 15, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasda...
Pulmatrix Quarterly report: Q1 2026
Pulmatrix has published its Q1 2026 quarterly earnings report on May 15, 2026.
Pulmatrix Earnings release: Q1 2026
Pulmatrix released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger
Series B Preferred Stock investment made in Pulmatrix with a conversion price of $2.20 is a part of the ongoing merger process FRAMINGHAM, Mass., April 21, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulma...
Pulmatrix to merge with Eos Senolytix
Pulmatrix (PULM) and Eos Senolytix, a biotechnology company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases, announced a definitive merger agree...
Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan
Combined company to operate as Eos SENOLYTIX, a first-in-class anti-aging biotechnology company $19 million financings to advance lead clinical candidate PTC-2105 for sarcopenia and age-related diseas...
Pulmatrix announces Cullgen terminates merger agreement
Pulmatrix (PULM) announced that on February 28, Cullgen notified Pulmatrix that Cullgen was terminating the Merger Agreement and related transactions thereunder. This termination follows the December ...
Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities
Cullgen had been seeking approval for a merger with Pulmatrix from the China Securities Regulatory Commission and on February 28, 2026, notified Pulmatrix that Cullgen was terminating the Merger Agree...
Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results
Plans to License or Monetize our Migraine and Inhalation Assets Continue FRAMINGHAM, Mass., Feb. 26, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceut...
Pulmatrix Annual report: Q4 2025
Pulmatrix has published its Q4 2025 annual report on February 26, 2026.
Pulmatrix Earnings release: Q4 2025
Pulmatrix released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.